OUR LADY OF BELLEFONTE
- Type
- Teaching hospital
- Where
- ASHLAND, KY
- Medicare CCN
- 180036
- Received
- $129,241 in 23 records, 2019 ($1,942 general, $127,299 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 3 | $1,942 |
| 2019 | Research payment | 20 | $127,299 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 17 | $102,704 | 2019 |
| Dova Pharmaceuticals | 3 | $24,595 | 2019 |
| Smith+Nephew, Inc. | 2 | $1,142 | 2019 |
| Insulet Corporation | 1 | $800 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 20 | $127,299 |
| Gift | 2 | $1,142 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $800 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-19 | Smith+Nephew, Inc. | $800 | Gift | In-kind items and services | Stravix Biological, Other Advanced Wound Management | 2019 | |
| 2019-12-17 | Dova Pharmaceuticals | $7,606 | Research payment | Cash or cash equivalent | Doptelet Drug, Hematology | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2019 |
| 2019-11-22 | Smith+Nephew, Inc. | $342 | Gift | In-kind items and services | Stravix Biological, Other Advanced Wound Management | 2019 | |
| 2019-10-30 | Merck Sharp & Dohme LLC | $2,233 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-10-16 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-10-16 | Merck Sharp & Dohme LLC | $97 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-07-08 | Insulet Corporation | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-07-02 | Dova Pharmaceuticals | $8,489 | Research payment | Cash or cash equivalent | Doptelet Drug, Hematology | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2019 |
| 2019-06-17 | Merck Sharp & Dohme LLC | $11,081 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-06-13 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-06-12 | Merck Sharp & Dohme LLC | $4,793 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-05-09 | Merck Sharp & Dohme LLC | $213 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2019 |
| 2019-04-25 | Merck Sharp & Dohme LLC | $11 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-03-26 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-02-27 | Merck Sharp & Dohme LLC | $16,246 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/A | 2019 |
| 2019-02-25 | Merck Sharp & Dohme LLC | $62 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-02-06 | Merck Sharp & Dohme LLC | $8,810 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-01-16 | Dova Pharmaceuticals | $8,500 | Research payment | Cash or cash equivalent | Doptelet Drug, Hematology | Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjec | 2019 |
| 2019-01-10 | Merck Sharp & Dohme LLC | $4,749 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-01-07 | Merck Sharp & Dohme LLC | $24,700 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-01-04 | Merck Sharp & Dohme LLC | $75 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-01-02 | Merck Sharp & Dohme LLC | $7,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-01-02 | Merck Sharp & Dohme LLC | $5,791 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Ashland, KY, county Boyd County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Ashland, KY | County Boyd County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 21,295 | 47,911 | 4,534,824 |
| Population, 2020 census P1 | 21,625 | 48,261 | 4,505,836 |
| Median age B01002 | 40.7 | 42.3 | 39.1 |
| Under 18 B01001 | 21.8% | 21.2% | 22.6% |
| 65 and over B01001 | 19.2% | 20.5% | 17.3% |
| Households B11001 | 9,439 | 19,309 | 1,814,469 |
| Foreign born B05002 | 1.8% | 1.3% | 4.7% |
| Median household income B19013 | $52,715 | $61,118 | $63,726 |
| Median family income B19113 | $67,824 | $73,492 | $81,505 |
| Per capita income B19301 | $32,025 | $31,752 | $35,821 |
| Poverty rate B17001 | 22.4% | 16.9% | 16.1% |
| Unemployment rate B23025 | 7.7% | 6.4% | 4.9% |
| Civilian labor force B23025 | 9,729 | 20,585 | 2,152,038 |
| Mean commute (minutes) B08013 | 20.9 | 22.1 | 24.0 |
| Bachelor's degree or higher B15003 | 24.8% | 20.0% | 27.6% |
| Housing units B25001 | 10,646 | 21,742 | 2,023,116 |
| Owner-occupied B25003 | 60.4% | 70.2% | 68.3% |
| Renters B25003 | 39.6% | 29.8% | 31.7% |
| Median home value B25077 | $125,000 | $130,700 | $205,600 |
| Median gross rent B25064 | $872 | $849 | $967 |
| White, not Hispanic B03002 | 91.2% | 92.2% | 81.5% |
| Black B03002 | 2.0% | 2.3% | 7.6% |
| Hispanic or Latino B03002 | 2.7% | 1.8% | 5.0% |
| Asian B03002 | 0.4% | 0.4% | 1.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Ashland, KY.
Comments